Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jun 15;27(2):23-30.
doi: 10.7812/TPP/22.073. Epub 2023 Jan 31.

The Use of Eculizumab for the Treatment of Atypical Hemolytic Uremic Syndrome in an Academic Hematology Center

Katharine Thomas  1 , Aneesha Ananthula  1 , Ruby Lopez-Flores  2 , Alejandra Del Toro  1 , Andrew G Chapple  3 , Michelle Loch  1
Affiliations

The Use of Eculizumab for the Treatment of Atypical Hemolytic Uremic Syndrome in an Academic Hematology Center

Katharine Thomas et al. Perm J. .

Abstract

Introduction Eculizumab is a complement inhibitor used in treating atypical hemolytic uremic syndrome (aHUS). This study showcases patient demographics, clinical and laboratory results of these patients, and overall outcomes of patients with aHUS treated with eculizumab. Methods The authors conducted a retrospective case study including 9 patients who received at least 1 dose of eculizumab for treating aHUS. A linear mixed effects model was used with random effects for each patient and fixed effects for eculizumab and time since admission. A p value < 0.05 was significant. Results Nine patients were treated with eculizumab for aHUS. Most patients were Black (n = 5) with either Medicare or Medicaid (n = 5). Genetic mutations were tested for in 5 patients. There were significant decreases in lactate dehydrogenase (LD, p = 0.029) and creatinine (Cr, p = 0.012) when on treatment. No significance was found in hemoglobin (p = 0.258) or platelets (p = 0.569). Treatment was stopped in 7 patients, of which 3 had no evidence of disease relapse. The only adverse event was severe thrombocytopenia (n = 1). Discussion This multicase study is the first of its kind in which most patients are Black, showing that there is a lack of research of this kind, especially on genetic mutations. Most of our patients did not have private insurance or had Medicaid/Medicare. There was a 246.5-day median duration of treatment. There was low risk of adverse events. Conclusion This case series elucidates the effective use of eculizumab for atypical hemolytic uremic syndromein a diverse patient population and emphasizes the need for more research in this area.

PubMed Disclaimer

Conflict of interest statement

Conflicts of InterestNone declared

Figures

Figure 1:
Figure 1:
Inclusion and exclusion criteria. aHUS = atypical hemolytic uremic syndrome.
Figure 2:
Figure 2:
Estimated time trends for each laboratory marker when on (solid) or off eculizumab (dotted line). Hg = hemoglobin.
Figure 3:
Figure 3:
Lactate dehydrogenase (LDH) response when on eculizumab treatment.
Figure 4:
Figure 4:
Creatinine response when on eculizumab treatment.
See this image and copyright information in PMC

References

    1. Noris M, Caprioli J, Bresin E, et al. . Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype. Clin J Am Soc Nephrol. 2010;5(10):1844–1859. 10.2215/CJN.02210310 - DOI - PMC - PubMed
    1. Mallett A, Hughes P, Szer J, et al. . Atypical haemolytic uraemic syndrome treated with the complement inhibitor eculizumab: The experience of the Australian compassionate access cohort. Intern Med J. 2015;45(10):1054–1065. 10.1111/imj.12864 - DOI - PubMed
    1. Caprioli J, Noris M, Brioschi S, et al. . Genetics of HUS: The impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome. Blood. 2006;108(4):1267–1279. 10.1182/blood-2005-10-007252 - DOI - PMC - PubMed
    1. Loirat C, Frémeaux-Bacchi V. Atypical hemolytic uremic syndrome. Orphanet J Rare Dis. 2011;6(1):1–30. 10.1186/1750-1172-6-60 - DOI - PMC - PubMed
    1. Tanimoto T, Oshima Y, Kami M. Eculizumab in atypical hemolytic-uremic syndrome. N Engl J Med. 2013;369(14):1378–1379. 10.1056/NEJMc1308826 - DOI - PubMed